Article

Meibomian Gland Diagnostic Expressibility: Correlation With Dry Eye Symptoms and Gland Location

Korb Associates, Boston, MA 02215, USA.
Cornea (Impact Factor: 2.36). 01/2009; 27(10):1142-7. DOI: 10.1097/ICO.0b013e3181814cff
Source: PubMed

ABSTRACT To determine (1) if the number of meibomian glands yielding liquid secretion (MGYLS) is correlated with dry eye symptoms and (2) the mean number of MGYLS in the nasal, central, and temporal regions of the lower eyelid in a random clinical sample.
Subjects presenting for routine eye examinations were recruited (n = 133; 90 females, 43 males; mean age = 50.3 +/- 14.7 years). The sample included symptomatic and asymptomatic individuals using the Standard Patient Evaluation of Eye Dryness questionnaire. Meibomian gland evaluations were performed using a standardized technique and diagnostic instrument.
The mean number of MGYLS in the lower eyelid correlated with dry eye symptoms, p = 0.0002. The mean numbers of MGYLS in each third of the lower eyelid were significantly different, p <or= 0.0001: temporal = 0.27 +/- 0.06, central = 2.14 +/- 0.13, and nasal = 3.10 +/- 0.15. The temporal third of the lower lid was 14 times as likely as the nasal third to have zero MGYLS; 86% of temporal versus 6% of nasal thirds had zero MGYLS.
This is the first report to document the following: (1) a correlation between the number of MGYLS in the lower eyelid and dry eye symptoms; (2) the number of MGYLS varies significantly across the lower eyelid, with the highest number of MGYLS in the nasal third and the lowest number of MGYLS in the temporal third of the lower eyelid; and (3) instrumentation to standardize diagnostic meibomian gland expression is desirable if not mandatory for the evaluation of meibomian gland function.

3 Followers
 · 
105 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The purpose of this study was to determine the clinical benefits of intense-pulsed-light therapy for the treatment of dry-eye disease caused by meibomian gland dysfunction (MGD). Background data: MGD is the leading cause of evaporative dry eye disease. It is currently treated with a range of methods that have been shown to be only somewhat effective, leading to the need for advanced treatment options. Methods: A retrospective noncomparative interventional case series was conducted with 91 patients presenting with severe dry eye syndrome. Treatment included intense-pulsed-light therapy and gland expression at a single outpatient clinic over a 30-month study. Pre/post tear breakup time data were available for a subset of 78 patients. For all patients, a specially developed technique for the treatment of dry eye syndrome was applied as a series of monthly treatments until there was adequate improvement in dry eye syndrome symptoms by physician judgment, or until patient discontinuation. Results: Primary outcomes included change in tear breakup time, self-reported patient satisfaction, and adverse events. Physician-judged improvement in dry eye tear breakup time was found for 68 of 78 patients (87%) with seven treatment visits and four maintenance visits on average (medians), and 93% of patients reported post-treatment satisfaction with degree of dry eye syndrome symptoms. Adverse events, most typically redness or swelling, were found for 13% of patients. No serious adverse events were found. Conclusions: Although preliminary, study results of intense-pulsed-light therapy treatment for dry eye syndrome caused by meibomian gland dysfunction are promising. A multisite clinical trial with a larger sample, treatment comparison groups, and randomized controlled trials is currently underway.
    Photomedicine and Laser Surgery 01/2015; 33(1):41-46. DOI:10.1089/pho.2014.3819 · 1.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sylentis is a Spanish biopharmaceutical company focused on developing compounds based on RNA interference for conditions of the anterior segment of the eye. Preclinical and clinical proof-of-concept has been achieved for glaucoma and ocular pain associated to dry eye. SYL040012 is a 21 nucleotide small interference RNA (siRNA) targeting beta 2 adrenergic receptor (ADRB2) and thus reduce production of aqueous humor. SYL1001 is a 19 nucleotide siRNA targeting TRPV1, a well-known nociceptor present in cornea and nerve terminals that innervate the cornea. Application of either siRNA in eye drops to animal models results in rapid absorption and distribution of the compounds into the anterior segment the eye. Very low levels of siRNA are found in systemic circulation or systemic tissues (<1ng/g tissue). SYL040012 has shown to reduce IOP in normotensive and hypertensive animal models; and this hypotensive effect is accompanied by reductions of approximately 40% of ADRB2 at the ciliary body. The results of the three clinical trials performed for SYL040012 showed that the siRNA has an excellent tolerance profile and that the dose of 300 ug/eye/day causes a statistically significant reduction in IOP when compared to placebo and to basal values. SYL1001 was shown to have analgesic effects in the capsaicin induced ocular pain rabbit model. One clinical trial has been completed for SYL1001, in said trial SYL1001 was very well tolerated and no ocular or systemic issues. An additional trial is ongoing in which safety and effect on ocular pain is being compared to placebo.
    11th ISOPT clinical. June 19-22, Reykjavik, Iceland, Bologna. Italia; 12/2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RNA interference (RNAi) is a relatively novel technology that is currently being exploited for therapeutic purposes for several indications. As of today, there is no approved therapy based on this technology but several compounds are in advanced phases of clinical development. The eye was one of the first settings in which proof of concept was achieved; but in the latest years successful development of delivery technologies to the liver have made this organ the preferred target of therapies based on RNAi. We have used the results obtained in preclinical and clinical development of several compounds for different ocular conditions to demonstrate that the eye represents an ideal organ for therapies based on RNAi.
    11th ISOPT, Reykjavik, Iceland; 06/2014